Prolastin-C Liquid: payments to doctors
Payments that named Prolastin-C Liquid as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.5M
- Providers
- 14,473
- Transactions
- 85,019
- Average per transaction
- $41
The per-transaction average — $41 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 14,473 providers the average total is $240, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Grifols USA, LLC | $3,317,299 | 95.6% |
| Grifols Shared Services North America, Inc. | $147,259 | 4.2% |
| Grifols, S.A. | $3,092 | 0.1% |
| Grifols Canada Ltd. | $2,576 | 0.1% |